Project description:Whole-exome sequencing was performed on DNA samples extracted from eight patient-derived melanoma cell lines grown in vitro in serum-free EGF/bFGF-containing medium. The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and response to drugs.
Project description:Whole-exome sequencing was performed on DNA sample extracted from one melanoma cell line resistant to vemurafenib (BRAF V600E inhibitor). The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and resistance to targeted therapeutics.
Project description:Whole-exome sequencing was performed on DNA samples extracted from seven melanoma cell lines resistant to either vemurafenib (BRAF V600E inhibitor) or trametinib (MEK1/2 inhibitor). The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and resistance to targeted therapeutics.
Project description:Whole-exome sequencing was performed on DNA samples extracted from seven melanoma cell lines resistant to either vemurafenib (BRAF V600E inhibitor) or trametinib (MEK1/2 inhibitor). The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and resistance to targeted therapeutics.
Project description:Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry - Exome sequencing
Project description:In recent years,Bap1 has been reported to be involved in the process of tumorigenesis. Bap1 gene mutations frequently occur in tumors such as uveal melanoma, mesothelioma, and kidney cancer. In our study,we found that Bap1 deletion in MC38 colon carcinoma cells can promote anti-tumor immune response. To investigate how the genetic mutational landscape,whole exome sequencing of MC38 colon carcinoma cells and MC38 Bap1-knockout cells were performed.
